Larvicides Market Size and Share

Larvicides Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Larvicides Market Analysis by Mordor Intelligence

The Larvicides Market size was valued at USD 0.95 billion in 2025 and estimated to grow from USD 1 billion in 2026 to reach USD 1.32 billion by 2031, at a CAGR of 5.69% during the forecast period (2026-2031). The market growth is driven by several factors, like the increasing necessity to target mosquitoes in their larval stage due to reduced effectiveness of adult mosquito control methods, expanded healthcare budgets in the Americas, and continuous development of environmentally compatible bio-rational formulations. Additional growth drivers include extended mosquito breeding periods in temperate regions, persistent dengue outbreaks in tropical urban areas, and increased adoption of integrated rice-fish farming systems requiring aquaculture-safe larvicides. The market faces challenges including higher production costs for biological products, inconsistent application methods in rural areas, and requirements for GIS-based monitoring systems to enhance treatment efficiency.

Key Report Takeaways

  • By product type, synthetic agents held 44.30% of the larvicides market share in 2025, whereas biological formulations are projected to expand at an 8.16% CAGR through 2031.
  • By control method, chemical agents dominated revenue in 2025, yet insect growth regulators are on track for a 7.62% CAGR to 2031.
  • By target insect, mosquitoes accounted for 64.40% share of the larvicides market size in 2025; the flies segment is forecast to grow at 6.34% CAGR.
  • By application, agricultural uses commanded 40.20% of the larvicides market size in 2025, while public-health programs are progressing at a 8.74% CAGR.
  • By region, North America led revenue in 2025, whereas South America is advancing at the fastest pace on the back of urban dengue control campaigns.

Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.

Larvicides Market Segment Analysis

By Product Type:

Biological Formulations Erode Synthetic Dominance

Synthetic larvicides account for 44.30% of the larvicides market share in 2025. Their market leadership stems from cost advantages and established procurement contracts. Biological products are growing at a higher rate of 8.16% CAGR, supported by government initiatives promoting integrated vector management approaches. Bacillus thuringiensis israelensis (Bti) demonstrates specific toxicity to mosquito larvae, blackflies, and fungus gnats. In 2023, the Kathmandu Metropolitan City (KMC) implemented bio-larvicide programs to control dengue outbreaks by targeting mosquito larvae. This organic solution eliminates mosquito larvae by disrupting their digestive systems while preserving other organisms.

The development of RNAi yeast larvicides in late-stage testing indicates potential market shifts, offering gene-specific control without affecting non-target species. Manufacturers are improving microencapsulation techniques to enhance product longevity and ease of use. Research in 2024 demonstrated the efficacy of botanical larvicides in crop protection, specifically marigold extracts. A study conducted by PES University in Bangalore revealed that Tagetes erecta and Tagetes patula contain thiophenes, which demonstrate significant larvicidal effects against crop pests Spodoptera litura and Corcyra cephalonica. These technological improvements, coupled with government incentives for environmentally sustainable products, enable biological larvicides to secure more municipal contracts.

Larvicides Market: Market Share by Product Type, 2025
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Larvicides Market: Market Share by Product Type, 2025

By Control Method:

IGRs Gain Momentum amid Resistance Concerns

Insect Growth Regulators (IGRs) have emerged as an effective larvicide control method, particularly in response to increasing resistance against conventional insecticides. IGRs disrupt mosquito development by inhibiting molting, reproduction, and metamorphosis, preventing larvae from reaching adulthood. While chemical contact poisons generated 54.10% of revenue in 2025, field studies indicate reduced effectiveness due to resistance development. Methoprene, a primary IGR compound, demonstrates effectiveness at concentrations of ≤ 10 ppb with minimal aquatic mobility.

Vector control programs are increasingly adopting IGR-based solutions, including pyriproxyfen and methoprene, due to widespread metabolic and behavioral resistance to pyrethroids and organophosphates. IGRs provide extended residual activity, reduced environmental impact, and lower resistance development risk, positioning them as integral components of sustainable mosquito control programs.

By Target Insect:

Mosquito Focus Sustains Volume, While Flies Offer Adjacent Growth

Mosquito control accounted for 64.40% of larvicide sales in 2025, driven by the continued public health threats of dengue, malaria, and West Nile virus infections. The market benefits from consistent demand through sustained control campaigns, established multi-year budgets, and donor-funded intervention programs. The World Health Organization reported over 7.6 million global dengue cases as of April 2024, an increase of 3 million cases compared to the previous year. In agricultural environments, mosquito-borne diseases like West Nile, Dengue, Zika, and Malaria affect worker health rather than causing direct crop damage.

According to the World Mosquito Program, dengue fever causes approximately 36,000 deaths globally each year, while yellow fever accounts for about 30,000 annual deaths. This ongoing disease burden requires continuous investment in mosquito control programs across both developed and developing regions, sustaining market demand for mosquito-targeted larvicides. The mosquito segment is projected to maintain its dominance in the target insect category throughout the forecast period.

By Application:

Public-Health Budgets Outpace Traditional Agriculture

Agriculture remains the primary revenue source in 2025, representing 40.20% of market share, as rice paddies, fishponds, and livestock operations incorporate larviciding into their standard practices. Municipal health agencies are increasing their investments at a faster rate. The Sacramento-Yolo Mosquito and Vector Control District has allocated USD 1.2 million for microbial larvicides and USD 1.2 million for biorationals in its 2024-2025 budget. Similar budget allocations in Florida, Texas, and Brazilian cities indicate sustained funding commitments.

Advanced delivery systems, including the In2Care trap, combine attractant, bio-agent, and automatic larvicide distribution to hard-to-reach areas. Implementation in residential areas enhances coverage efficiency, supporting higher price points. Throughout the forecast period, public health regulations will gradually alter volume distribution across channels, driving double-digit growth for specialized suppliers.

Larvicides Market: Market Share by Application, 2025
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Larvicides Market: Market Share by Application, 2025

By Formulation:

Tablets and Pellets Accelerate on Labor Savings

Liquid suspensions accounted for 45.30% of shipments in 2025, primarily due to their ease of tank mixing and versatility across different habitats. Controlled-release tablets and pellets are experiencing a 7.07% CAGR, driven by their ability to reduce repeated application labor in difficult-to-access habitats. Field trials in Vietnamese rice paddies demonstrated that floating tablets maintained over 70% efficacy for 21 days, exceeding sinking variants by 10.7%.

Manufacturers are developing biodegradable wax carriers that maintain buoyancy and protect spores from UV degradation. In 2024, the Town of Westerly conducted an aerial application of mosquito larvicide over Chapman Swamp to reduce mosquito-borne illnesses. The operation involved distributing pellets of Bacillus thuringiensis israelensis (Bti), a naturally occurring bacterium that specifically targets mosquito larvae without affecting humans or beneficial insects. The Rhode Island Department of Environmental Management (DEM) supervised the process.

Geography Analysis

North America Larvicides Market

North America generated the largest regional revenue in 2024, supported by structured vector-management frameworks and rising concern over West Nile and Eastern equine encephalitis. The United States is the primary user of larvicides for mosquito and larva control in North America. The Centers for Disease Control and Prevention (CDC) and local mosquito control districts implement vector control programs across the country. These programs incorporate larvicides within integrated mosquito management (IMM) strategies to prevent diseases such as West Nile virus, Zika, and other mosquito-borne illnesses.

United States Larvicides Market

The Environmental Protection Agency (EPA) endorses multiple larval mosquito control methods that target immature mosquitoes in their early stages. These methods include:- Bacterial insecticides (Bacillus thuringiensis israelensis and Bacillus sphaericus) that disrupt larval digestion - Insect growth inhibitors like methoprene that prevent development - Surface oils and films that cause larvae to drown. Environmental concerns have resulted in the discontinuation of certain control methods, particularly organophosphate insecticides. All control methods must comply with regulations to protect vulnerable populations. The EPA's 2026 Pesticide General Permit has established strict requirements for pesticide applications to surface waters, which shape product development throughout North America.

APAC Larvicides Market

Asia presents a diverse mix; China and India anchor volume through agricultural applications, while Southeast Asian markets leverage subsidies that mandate biological larvicides in rice-fish systems. Simultaneously, Aedes aegypti resistance to organophosphates and pyrethroids forces councils in Indonesia to rotate IGRs and Bti combinations, underpinning incremental unit growth. The larvicide market share attributable to Asia will expand each year of the outlook, yet margins may stay compressed given price sensitivity in several economies.

Brazil Larvicides Market

South America demonstrates the highest growth rate, driven by public health crises related to dengue and chikungunya outbreaks. Brazil reported 7.25 million dengue cases in 2024, exceeding twice the number recorded in 2023, prompting increased Bti investments across federal, state, and municipal governments. Urban sanitation departments combine source reduction initiatives with weekly larvicide applications, ensuring consistent product demand that maintains distributor inventory levels.

Larvicides Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Regulatory Landscape

Larvicides are regulated primarily as pesticides, with tighter environmental safeguards influencing active-ingredient choice and application documentation for water-associated use cases. In the United States, the US Environmental Protection Agency (EPA) finalized the 2026 National Pollutant Discharge Elimination System (NPDES) Pesticide General Permit in December 2024. The permit framework for 2026-2031 reinforces requirements such as use-site documentation and monitoring for surface-water applications, which affects municipal larviciding programs and the suppliers serving them.

In Europe, recent regulatory updates add packaging and formulation compliance work for suppliers of crop-protection and vector-control chemistries. Regulation (EU) 2026/1123 (May 2026) updates labeling requirements for plant protection products to align with CLP (Regulation (EC) 1272/2008), while Regulation (EU) 2026/1120 (May 2026) amends Regulation (EC) 1107/2009 by adding co-formulants deemed unacceptable, increasing reformulation pressure for certain products. In Canada, Health Canada published Proposed Registration Decision PRD2026-07 in 2026 for AQUABAC II XT (Bacillus thuringiensis subsp. israelensis) for greenhouse non-food use, reflecting continued regulatory pathways for biological larvicides alongside tighter oversight for aquatic exposure scenarios.

Value Chain Analysis

The larvicide value chain begins with active ingredient and input supply, splitting between petrochemical-derived synthetics (including legacy organophosphate and IGR chemistries) and biologically derived actives produced via fermentation, notably Bacillus thuringiensis israelensis and related strains. Biological supply chains tend to be more sensitive to fermentation inputs and quality control, while synthetics depend on upstream chemical intermediates and large-scale technical manufacturing. In both pathways, registration dossiers, toxicology packages, and label claims determine which formulations move downstream into public-health tenders and agricultural channels.

Formulation and packaging are followed by distribution through two main routes: (i) public-health procurement, where suppliers deliver under direct service contracts to mosquito control districts and municipal programs, and (ii) agriculture, where products move through cooperatives and independent retail networks in rice belts and livestock systems. Compliance and licensing are jurisdiction-specific, shaping go-to-market structures; for example, India routes insecticide market access through Central Insecticides Board and Registration Committee (CIB&RC) registration and state-level manufacturing licenses, which can favor local formulators and packers. Adoption of drone-based or GIS-guided application adds a services layer (mapping, documentation, and application capability) that increasingly differentiates vendors beyond the active ingredient alone.

Competitive Landscape

The market structure remains moderately concentrated, with BASF SE, Bayer AG, and Syngenta AG controlling over 50% of synthetic pesticide volume. These companies utilize multi-crop distribution networks and extensive product registrations as barriers to entry. In the biological segment, Valent BioSciences, Certis Biologicals, and Sumitomo Chemical Corporation (parent company of VectoBac) are increasing their capital investments to address growing demand. Valent's planned 2025 expansion of Bti fermentation facilities in the United States aims to ensure a reliable supply for Latin American contracts.

Strategic alliances emerge as a mechanism to blend formulation skills with market reach. Central Life Sciences licenses granular IGR technology to regional formulators that localize packaging sizes for African cooperatives. Several startups negotiate co-development agreements with genomic-editing firms to commercialize RNAi yeast larvicides, securing intellectual-property positions that differentiate from commoditized chemistries.

Research and development focus on improving long-term pest control effectiveness while meeting environmental safety standards. Field testing data supports regulatory approval applications, and securing early approvals can lead to long-term municipal contracts that strengthen market position. As a result, suppliers increasingly compete by providing comprehensive data demonstrating product performance in specific local breeding environments.

Larvicides Industry Leaders

  1. Syngenta AG

  2. BASF SE

  3. Sumitomo Chemical Co.

  4. Certis Biologicals

  5. Bayer AG

  6. *Disclaimer: Major Players sorted in no particular order
Larvicides Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Larvicides Market Companies Covered in this Report

  • BASF SE
  • Bayer AG
  • Syngenta AG
  • Sumitomo Chemical Co.
  • Clarke Mosquito Control Products Inc.
  • Central Life Sciences
  • Certis Biologicals
  • UPL Ltd.
  • FMC Corporation
  • Russell IPM

Read Analysis of Larvicides Companies

Market Opportunities and Future Outlook

Tightening aquatic and biodiversity safeguards is creating room for suppliers that can combine proven larval efficacy with lower non-target risk and stronger documentation, particularly in public-health programs that treat storm drains, marshes, and other surface-water habitats. The US EPA 2026 NPDES Pesticide General Permit framework, together with the EPA Insecticide Strategy finalized in April 2025, increases the operational value of products supported by robust data packages and digital-ready application records. This supports differentiated offerings in microbial larvicides and IGRs where compliance burden is highest.

Technology-led opportunities are also clustering around longer-lasting and more precise delivery formats that reduce re-application labor and improve coverage of hard-to-access breeding sites. In 2026, academic evidence highlighted nano-formulated biopesticides, including nano-encapsulated Bti, with reported 30-50% increases in field persistence and efficacy versus conventional formulations, pointing to formulation innovation pathways for vendors with Bti-based portfolios. At the same time, consolidation of biological assets by suppliers serving vector control, including Clarke expanding control over Bti and Lysinibacillus sphaericus larvicide lines through acquisitions, reflects pull for integrated microbial portfolios that can be rotated for resistance management across municipalities and high-pressure agricultural water systems.

Recent Industry Developments in Larvicides Market

  • March 2026: BASF Agricultural Solutions completed its acquisition of AgBiTech, expanding its biological insect control portfolio. The acquisition supports BASF's biologicals footprint in key markets such as Brazil and backs broader integrated pest management positioning alongside conventional crop-protection channels.
  • January 2026: Clarke completed the acquisition of the Spheratax larvicide portfolio from Advanced Microbiologics, adding Lysinibacillus sphaericus-based larvicide assets. The transaction expands Clarke's microbial larvicide toolkit for mosquito control programs and reinforces portfolio rotation options for resistance management.
  • December 2024: The US Environmental Protection Agency (EPA) issued the final 2026 NPDES Pesticide General Permit for point source discharges of biological and chemical pesticides. The permit raises the bar on documentation and monitoring for surface-water applications, shaping product selection and service requirements for larvicide suppliers serving municipalities and vector control districts.

Table of Contents for Larvicides Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Surge in insecticide-resistant adult mosquitoes
    • 4.2.2 Roll-out of dengue and chikungunya prevention programs
    • 4.2.3 Climate-induced expansion of mosquito breeding seasons
    • 4.2.4 Government subsidies for integrated rice-fish farming
    • 4.2.5 Regulatory Policies on Larvicides
    • 4.2.6 Rapid scale-up of drone-based aerial application of larvicides
  • 4.3 Market Restraints
    • 4.3.1 Stringent aquatic-toxicity thresholds limiting chemical formulations
    • 4.3.2 Low adoption of GIS breeding-site mapping curbing commercial sales
    • 4.3.3 Supply-chain volatility for Bacillus fermentation media
    • 4.3.4 Public pressure against synthetic vector-control compounds
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porters Five Forces
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size and Growth Forecasts

  • 5.1 By Product Type
    • 5.1.1 Synthetic Larvicides
    • 5.1.2 Biological Larvicides
  • 5.2 By Control Method
    • 5.2.1 Chemical Agents
    • 5.2.2 Biocontrol Agents
    • 5.2.3 Insect Growth Regulators (IGR)
  • 5.3 By Target Insect
    • 5.3.1 Mosquitoes
    • 5.3.2 Flies
    • 5.3.3 Beetles
    • 5.3.4 Ants
  • 5.4 By Application
    • 5.4.1 Agriculture
    • 5.4.2 Non Agriculture
  • 5.5 By Formulation
    • 5.5.1 Granules
    • 5.5.2 Liquids and Suspensions
    • 5.5.3 Pellets and Tablets
    • 5.5.4 Powders and Wettable Dusts
  • 5.6 By Geography
    • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
    • 5.6.1.4 Rest of North America
    • 5.6.2 South America
    • 5.6.2.1 Brazil
    • 5.6.2.2 Argentina
    • 5.6.2.3 Rest of South America
    • 5.6.3 Europe
    • 5.6.3.1 United Kingdom
    • 5.6.3.2 Germany
    • 5.6.3.3 France
    • 5.6.3.4 Italy
    • 5.6.3.5 Spain
    • 5.6.3.6 Rest of Europe
    • 5.6.4 Africa
    • 5.6.4.1 South Africa
    • 5.6.4.2 Nigeria
    • 5.6.4.3 Egypt
    • 5.6.4.4 Rest of Africa
    • 5.6.5 Middle East
    • 5.6.5.1 Saudi Arabia
    • 5.6.5.2 United Arab Emirates
    • 5.6.5.3 Qatar
    • 5.6.5.4 Rest of Middle East
    • 5.6.6 Asia-Pacific
    • 5.6.6.1 China
    • 5.6.6.2 India
    • 5.6.6.3 Japan
    • 5.6.6.4 Australia
    • 5.6.6.5 Rest of Asia-Pacific

6. Competitive Landscape

  • 6.1 Strategic Moves
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)}
    • 6.3.1 BASF SE
    • 6.3.2 Bayer AG
    • 6.3.3 Syngenta AG
    • 6.3.4 Sumitomo Chemical Co.
    • 6.3.5 Clarke Mosquito Control Products Inc.
    • 6.3.6 Central Life Sciences
    • 6.3.7 Certis Biologicals
    • 6.3.8 UPL Ltd.
    • 6.3.9 FMC Corporation
    • 6.3.10 Russell IPM

7. Market Opportunities and Future Outlook

Larvicides Market Report Scope and Research Methodology

Market Definition and Coverage

This market covers the value of larvicide products used to control insects at the larval stage, across public health and agricultural use. The sizing reflects sales of finished larvicide formulations supplied through common commercial and municipal channels.

Scope exclusions: adulticides, fogging or spraying equipment, and physical traps are excluded from this market sizing.

Segments Covered in This Report

  • By Product Type
    • Synthetic Larvicides
    • Biological Larvicides
  • By Control Method
    • Chemical Agents
    • Biocontrol Agents
    • Insect Growth Regulators (IGR)
  • By Target Insect
    • Mosquitoes
    • Flies
    • Beetles
    • Ants
  • By Application
    • Agriculture
    • Non Agriculture
  • By Formulation
    • Granules
    • Liquids and Suspensions
    • Pellets and Tablets
    • Powders and Wettable Dusts
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
      • Rest of North America
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Africa
      • South Africa
      • Nigeria
      • Egypt
      • Rest of Africa
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Rest of Middle East
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • Rest of Asia-Pacific

Data Sources, Market Sizing, and Validation

Desk Research

Desk research was used to set the foundation for the model and to pressure-test early assumptions before interviews were run. We relied on public sources such as the World Health Organization guidance on vector control, FAO statistics on crop area and pest pressure, and US EPA and EU pesticide registration and active-ingredient information to understand what is permitted and what is actually used.

To connect the scope to real demand signals, we also reviewed sources such as national public health program updates, government procurement notices where available, and import and export trade statistics for relevant pesticide categories. General secondary sources like company annual reports, investor presentations, and reputable press coverage were used to map routes to market and pricing narratives. In a few places, paid subscriptions for company financials and patent databases helped confirm product pipelines and revenue exposure, though the final sizing still depended on traceable market variables. The desk sources listed here are illustrative, and many other public references were also used for data collection, validation, and clarification.

Primary Interviews and Surveys

Primary work focused on filling practical gaps that public information does not answer well, especially how product mix, dosage practices, and channel markups vary by end user. We spoke with manufacturers, distributors, municipal and public health stakeholders, and field-level applicators across APAC, EMEA, and the Americas so assumptions could be checked region by region before final totals were locked.

Distribution of primary research fieldwork respondents

Company typeRespondent positionRegion
Top tier: 32% CXOs: 18%APAC: 38%
Mid tier: 50% Functional/Unit leaders: 38%EMEA: 35%
Smaller Players: 18% Managers: 44%Americas: 27%

Market-Sizing & Forecasting

Market size was built using a top-down model where public health demand pools and agricultural use patterns are reconstructed from population at risk, program coverage, crop area, and treatment intensity, and then converted into value using typical dosage and average selling price ranges. To keep totals realistic, selective bottom-up approximations were used as a check, such as supplier revenue exposure by region, channel interviews on municipal tender volumes, and sampled price points across common formulations.

Key inputs in this market included the share of vector-control budgets allocated to larval control, frequency of applications in standing-water sites, seasonality tied to rainfall and mosquito breeding cycles, product mix shifts between biological and chemical options, and price differences by formulation (for example granules versus liquids). Where direct volume signals were weak in a country, we used proxy indicators like outbreak history, urbanization, and program maturity, then adjusted the implied per-capita or per-hectare use through interviews.

For forecasting, scenario analysis was used alongside simple multivariate regression so growth could be linked to drivers that can be monitored each year, such as reported disease incidence, policy tightening on certain chemistries, and expected funding for public health operations. Assumptions were reviewed with primary respondents to avoid overly aggressive uptake curves in regions where execution capacity is constrained.

Data Validation & Update Cycle

Validation was handled through repeated cross-checks between model outputs and independent signals, including public procurement activity, registration pipelines, and observed pricing ranges by formulation. When results looked inconsistent, we revisited the assumptions, re-checked units, and, where needed, re-contacted interviewees to confirm whether the variance came from timing, channel margins, or a scope mismatch.

Before sign-off, the model and written assumptions go through multi-step analyst review so arithmetic errors and logic issues are caught early. The report is refreshed annually, and interim updates are made when material events occur, such as major regulatory shifts or unusually large vector-control funding changes. Right before delivery, a final pass is completed so clients receive the most current view that can be supported by the latest available evidence.

Mordor Intelligence's Larvicides Market Estimate Compared With Other Published Estimates

Published market numbers for larvicides can look far apart because the scope lines are not always drawn the same way, and because pricing and volume assumptions are refreshed at different times. Differences usually show up around whether the estimate is tied to public health purchasing, agricultural use, or a blended view that mixes several adjacent pest-control categories.

Adult mosquito adulticides sit outside Mordor Intelligence's scope for this larvicides market, which is one clear reason some published totals run higher when they bundle larval and adult control products together. The spread can also come from how each publisher treats formulation mix, how they move prices forward (flat pricing versus inflation-adjusted ASPs), and whether currency conversion is done on a single-year average rate or a multi-year smoothing approach.

Benchmark comparison

SourceMarket SizeGaps in Research Methodology
Mordor Intelligence USD 1.00 B (2026)
Global Consultancy A USD 0.99 B (2024)Uses an earlier base year and appears to blend control methods and end uses without clearly separating municipal vector-control demand from agricultural uses, which can shift implied volumes and pricing.
Industry Publisher B USD 0.79 B (2024)Focuses heavily on government, commercial, and residential applications and provides limited clarity on agricultural inclusion, which can understate the total when crop-related larvicide demand is material in certain regions.

The table shows that most of the gap is explained by what gets counted in the market basket and how the base year is set, rather than by one single growth assumption. By keeping the demand pool traceable to program coverage, application intensity, and region-level pricing checks, the estimate stays easier to reproduce and update when new public health or regulatory signals emerge.

Key Questions Answered in the Report

What is the current size of the larvicides market and how fast is it growing?

The larvicides market is valued at USD 1 billion in 2026 and is on track to reach USD 1.32 billion by 2031, reflecting a 5.69% CAGR.

Which product type is expanding fastest within the larvicides industry?

Biological larvicides, particularly Bti formulations, are advancing at an 8.16% CAGR because they address resistance and comply with strict aquatic-toxicity requirements.

Why are insect growth regulators gaining popularity?

IGRs such as methoprene disrupt mosquito development without high acute toxicity, making them effective where resistance to conventional chemistries has emerged and helping programs meet environmental standards.

Which region offers the strongest growth prospects for larvicides suppliers?

South America, driven by large-scale dengue control campaigns in Brazil and neighboring countries, is the fastest-growing regional market over the 2026-2031 period.

How are regulatory changes influencing product development?

The US EPA’s tighter limits on aquatic toxicity under the Clean Water Act are accelerating industry investment in low-impact microbial and IGR solutions, encouraging suppliers to phase out higher-risk organophosphates.

What role does climate change play in larvicide demand?

Longer and warmer breeding seasons in temperate zones are extending treatment windows and increasing orders for sustained-release formulations that remain active for several months.

Page last updated on: